Welcome!

News Feed Item

Pieris Pharmaceuticals Reports Full-Year 2017 Financial Results and Corporate Update

Company to Host an Investor Conference Call on Friday, March 9, 2018 at 8:00 Am Est

BOSTON, MA--(Marketwired - March 09, 2018) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today financial results for its fiscal year ended December 31, 2017, and provided a corporate update:

  • PRS-343: Pieris continues to advance PRS-343, a tumor-targeted 4-1BB-based immuno-oncology (IO) bispecific, through a phase 1, dose-escalation study, with initial safety, tolerability, pharmacokinetic and pharmacodynamic data expected in the second half of 2018. This program is the first bispecific T cell costimulatory agonist to enter clinical development.
  • PRS-060: The company continues to enroll healthy subjects in a first-in-human study for PRS-060, an IL-4 receptor alpha antagonist, which began during the fourth quarter of 2017. PRS-060 is the lead product in the company's respiratory alliance with AstraZeneca. Pieris is sponsoring the phase 1 study, while AstraZeneca is responsible for funding its costs. Initial data from the phase 1 study are expected in the fourth quarter of 2018. AstraZeneca will sponsor and continue to fund clinical development of PRS-060 through phase 2a, after which the company may exercise an option to co-develop PRS-060. Pieris also has an option for U.S. co-commercialization rights for this program.
  • PRS-080: Pieris continues to enroll dialysis-dependent patients with functional iron deficiency anemia in a phase 2a study for PRS-080. Pieris intends to report safety and pharmacodynamic data from this study, including the change in hemoglobin levels after five weekly doses of PRS-080, in the second half of 2018. If data are positive, the company will seek to partner PRS-080 in territories outside of those for which ASKA Pharmaceutical Co. has an exclusive option (Japan and certain other Asian territories).
  • Seattle Genetics Collaboration: On February 9, 2018, the company announced a multi-program IO-focused alliance with Seattle Genetics. The collaboration leverages the expertise and core technologies of both companies to develop novel Antibody-Anticalin bispecific fusion proteins utilizing Seattle Genetics' tumor-targeted monoclonal antibodies and Pieris' costimulatory engaging Anticalin proteins. Under the collaboration, Seattle Genetics will pay Pieris a $30 million upfront fee. Pieris has the potential to receive up to $1.2 billion in success-based payments in addition to royalties up to the double digits in connection with the sales of commercialized products, as well as an option to co-develop and commercialize one of the programs in the U.S.
  • Equity Financing: In February 2018, the company completed an underwritten public offering in which it sold 6,325,000 shares of common stock, including the full exercise of the over-allotment of an additional 825,000 shares, to the public at a price of $8.00 per share. Net proceeds of the underwritten public offering, after deducting the underwriting discounts and commissions and financing costs, were $47.3 million.
  • Cash Position: Cash, cash equivalents and investments totaled $82.6 million as of December 31, 2017. This amount excludes payment of a $12.5 million milestone from AstraZeneca achieved in the fourth quarter of 2017, the $47.3 million in net proceeds from the February 2018 equity financing, and the $30.0 million upfront payment due from Seattle Genetics.

"2017 was a transformational year for Pieris, as we advanced our lead respiratory and IO drug candidates into the clinic, while advancing PRS-080 into a phase 2a study and entering into two major alliances, in respiratory diseases and IO, bringing increased validation to our R&D strategy while retaining commercial rights on several partnered programs and strengthening our cash position," said Stephen S. Yoder, President and CEO. "This momentum continued into 2018 as we signed a significant IO collaboration agreement with Seattle Genetics. We are developing three clinical-stage programs, data from all of which are projected to be available later this year. In addition, we continue to build long-term value by advancing multiple preclinical IO programs with the intention to file two new INDs in 2019, while engaging in a broad research effort developing novel Anticalin proteins against multiple targets in both IO and respiratory diseases. We look forward to sharing data across our pipeline later this year."

Fiscal Year Financial Update:

Cash Position - Cash, cash equivalents and investments totaled $82.6 million as of December 31, 2017, compared to a cash balance of $29.4 million as of December 31, 2016. The increase was driven primarily by a $45.0 million upfront payment received as part of the AstraZeneca respiratory alliance, a EUR30.0 million (approximately $32.0 million) upfront payment received from Servier, and a $2.8 million option payment received from ASKA. This was offset by $39.3 million of operating cash expenditures during the year.

R&D Expense - R&D expenses were $22.3 million for the year ended December 31, 2017, compared to $19.7 million for the year ended December 31, 2016. The Company's increase in R&D expenses reflects advancement across its pipeline of programs as well as preparation for and advancement of clinical studies.

G&A Expense - G&A expenses for the year ended December 31, 2017 were $17.6 million, compared to $8.9 million for the year ended December 31, 2016. The increase in the 2017 period as compared to the corresponding period in 2016 is attributable in part to transaction fees associated with the company's partnership agreements and investments in our G&A functions including personnel costs, recruiting costs, and professional services (audit, tax, legal and communications) to support the growing business.

Net Loss - Net loss was $17.6 million or $(0.40) per share for the year ended December 31, 2017, compared to a net loss $22.8 million or $(0.55) per share for the year ended December 31, 2016.

Conference Call:

Pieris management will host a conference call beginning at 8:00 AM Eastern Standard Time on Friday, March 9, 2018, to discuss the full year financial results and provide a corporate update. You can join the call by dialing +1-877-407-8920 (US & Canada) or +1-412-902-1010 (International). An archived replay of the call will be available by dialing +1-877-660-6853 (US & Canada) or +1-201-612-7415 (International) and providing the Conference ID #: 13661472.

About Pieris Pharmaceuticals

Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor microenvironment, an inhaled Anticalin protein to treat uncontrolled asthma and a half-life-optimized Anticalin protein to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin® is a registered trademark of Pieris. For more information, visit www.pieris.com.

Forward Looking Statements

This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to novel technologies and methods; our business and product development plans; the timing and progress of our studies, including the timing of enrollment and dosing of PRS-343 patients and PRS-060 healthy subjects; the enrollment of patients in the PRS-080 multi-dose trial and dosing healthy subjects; our liquidity and ability to fund our future operations; our ability to achieve certain milestones and receive future milestone or royalty payments; or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding we will need to continue to pursue our business and product development plans; the inherent uncertainties associated with developing new products or technologies and operating as a development stage company; our ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates, including our ability to recruit and enroll patients in our studies; our ability to address the requests of the FDA; competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents we file with the SEC available at www.sec.gov, including without limitation the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and the Company's Quarterly Reports on Form 10-Q.

                                                                            
                        PIERIS PHARMACEUTICALS, INC.                        
                    CONDENSED CONSOLIDATED BALANCE SHEETS                   
                               (In thousands)                               
                                                                            
                                                   December 31, December 31,
                                                       2017         2016    
                                                   ------------ ------------
Assets:                                                                     
  Cash and cash equivalents                        $     37,878 $     29,356
  Short term investments                                 34,751            -
  Accounts receivable                                    15,546           57
  Prepaid expenses and other current assets               1,615        3,260
                                                   ------------ ------------
Total current assets                                     89,790       32,673
                                                   ------------ ------------
Property and equipment, net                               4,034        2,264
Long term investments                                     9,922            -
Other non-current assets                                    130          126
                                                   ------------ ------------
Total Assets                                       $    103,876 $     35,063
                                                   ============ ============
Liabilities and stockholders' equity:                                       
  Accounts payable                                 $      2,452 $      2,386
  Accrued expenses                                        6,170        3,719
  Deferred revenue, current portion                      37,153        2,275
                                                   ------------ ------------
Total current liabilities                                45,775        8,380
                                                   ------------ ------------
Deferred revenue, net of current portion                 46,542        1,409
Other long-term liabilities                                  37           47
                                                   ------------ ------------
Total Liabilities                                        92,354        9,836
                                                   ------------ ------------
Total stockholders' equity                               11,522       25,227
                                                   ------------ ------------
Total liabilities and stockholders' equity         $    103,876 $     35,063
                                                   ============ ============
                                                                            
                                                                            
                        PIERIS PHARMACEUTICALS, INC                         
              CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS               
                   (In thousands, except per share data)                    
                                                                            
                                                   Years Ended December 31, 
                                                       2017         2016    
                                                   -----------  ----------- 
Revenues                                           $    25,275  $     5,831 
Operating expenses                                                          
  Research and development                              22,285       19,699 
  General and administrative                            17,584        8,891 
                                                   -----------  ----------- 
Total operating expenses                                39,869       28,590 
Loss from operations                                   (14,594)     (22,759)
  Interest income, net                                     152            2 
  Other income (expense), net                           (2,102)         120 
                                                   -----------  ----------- 
Loss before income taxes                               (16,544)     (22,637)
  Provision for income tax                               1,103          162 
                                                   -----------  ----------- 
Net loss                                           $   (17,647) $   (22,799)
                                                   ===========  =========== 
Basic and diluted net loss per share               $     (0.40) $     (0.55)
                                                   ===========  =========== 
Basic and diluted weighted average shares                                   
 outstanding                                            43,931       41,713 
                                                   ===========  =========== 
                                                                            

Company Contact:
Allan Reine
SVP & Chief Financial Officer
+1-857-444-4276
[email protected]

Investor Relations Contact:

The Trout Group
Thomas Hoffmann
+1-646-378-2931
[email protected]

Media Inquiries:

Trophic Communications
Gretchen Schweitzer
+49 89 238 87730
[email protected]

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
Cryptomage, Inc. is a dynamic hi-tech ICT company offering products and services in the cybersecurity area. We deliver high quality solutions both technologically and conceptually. We have academic roots and hire scientists, cybersecurity experts, software developers and analysts. Our strategy is focused on maintaining the highest skills of our human resources. The Cryptomage team is capable of more than delivering complex solutions; we can improve the whole concept to deliver real added value t...
In addition to 22 Keynotes and General Sessions, attend all FinTechEXPO Blockchain "education sessions" plus 40 in two tracks: (1) Enterprise Cloud (2) Digital Transformation. PRICE EXPIRES AUGUST 31, 2018. Ticket prices: ($295-Aug 31) ($395-Oct 31) ($495-Nov 12) ($995-Walk-in) Does NOT include lunch.
Early Bird Registration Discount Expires on August 31, 2018 Conference Registration Link ▸ HERE. Pick from all 200 sessions in all 10 tracks, plus 22 Keynotes & General Sessions! Lunch is served two days. EXPIRES AUGUST 31, 2018. Ticket prices: ($1,295-Aug 31) ($1,495-Oct 31) ($1,995-Nov 12) ($2,500-Walk-in)
It cannot be overseen or regulated by any one administrator, like a government or bank. Currently, there is no government regulation on them which also means there is no government safeguards over them. Although many are looking at Bitcoin to put money into, it would be wise to proceed with caution. Regular central banks are watching it and deciding whether or not to make them illegal (Criminalize them) and therefore make them worthless and eliminate them as competition. ICOs (Initial Coin Offer...
DevOpsSUMMIT at CloudEXPO will expand the DevOps community, enable a wide sharing of knowledge, and educate delegates and technology providers alike. Recent research has shown that DevOps dramatically reduces development time, the amount of enterprise IT professionals put out fires, and support time generally. Time spent on infrastructure development is significantly increased, and DevOps practitioners report more software releases and higher quality. Sponsors of DevOpsSUMMIT at CloudEXPO will b...
Today we introduced our New York & Silicon Valley combo sponsorship and exhibit opportunities with unmatched pre and post-show promotion. At CloudEXPO | DevOpsSUMMIT | DXWorldEXPO NY & CA, Digital Transformation (DX) is a major focus with the introduction of DXWorldEXPO within the program. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive over the long term. A total of 88% of Fortune...
FinTech Is Now Part of the CloudEXPO New York Program. Financial enterprises in New York City, London, Singapore, and other world financial capitals are embracing a new generation of smart, automated FinTech that eliminates many cumbersome, slow, and expensive intermediate processes from their businesses. Accordingly, attendees at the upcoming 22nd CloudEXPO | DXWorldEXPO November 12-13, 2018 in New York City will find fresh new content in two new tracks called: FinTechEXPO New York Blockchain E...
In addition to 22 Keynotes and General Sessions, pick from 40 technical sessions in two tracks: (1) DevOpsSUMMIT (2) Cloud-Native & Serverless. EXPIRES AUGUST 31, 2018. Ticket prices: ($295-Aug 31) ($395-Oct 31) ($495-Nov 12) ($595-Walk-in) Does NOT include lunch. DevOps Institue Certification DevOps Institute Two-Day DevOps Certification Program EXPIRES AUGUST 31, 2018. Ticket prices: ($995-Aug 31) ($1,095-Oct 31) ($1,195-Nov 12) ($1,395-Walk-in)
Enterprises are universally struggling to understand where the new tools and methodologies of DevOps fit into their organizations, and are universally making the same mistakes. These mistakes are not unavoidable, and in fact, avoiding them gifts an organization with sustained competitive advantage, just like it did for Japanese Manufacturing Post WWII.
Only Adobe gives everyone - from emerging artists to global brands - everything they need to design and deliver exceptional digital experiences. Adobe Systems Incorporated develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. The Company's Digital Media segment provides tools and solutions that enable individuals, small and medium businesses and enterprises to cre...
Despite being the market leader, we recognized the need to transform and reinvent our business at Dynatrace, before someone else disrupted the market. Over the course of three years, we changed everything - our technology, our culture and our brand image. In this session we'll discuss how we navigated through our own innovator's dilemma, and share takeaways from our experience that you can apply to your own organization.
Blockchain has numerous revolutionary ambitions, but technology hasn’t evolved enough to make them practical. What is the best use of blockchain technology today? How are asset owners and managers looking at blockchain to transform ownership structures? How will blockchain technology allow global investors to access new markets? What kinds of companies will take advantage of blockchain technology as a more efficient way to raise capital?
This session describes how Professional Services organisations can deliver within Technology-as-a-Service (IaaS) constructs, in private and public enterprise cloud scenarios. See how professional services can be packaged and funded by IaaS cash flows, based upon consumption of technology services. Learn how significant, IT infrastructure transformations can be funded through OPEX spending models with multi-year As-a-Services based contracts. Understand how the automation of repeatable services c...
Since their inception, Total Uptime has been delivering on their promise of unprecedented uptime to major brands as well as Fortune 500 corporations in the United States and around the world. Their Cloud network spans 17 countries and delivers the unique ability to seamlessly route Internet traffic from one site to the next when our customers need us to. It is built on the best SSAE 16 SOC 2 Type 2 and CSAE 3416 Datacenters and boasts an impressive line-up of Network and Transit Provider Redunda...
​Blockchain, also known as Distributed Ledger Technology (DLT), can be used for more than just crypto currencies. This presentation discusses how blockchain and the Internet of Things (IOT) can be used for several supply chain management and logistics use cases. Real world examples that utilize the open source project Hyperledger will be discussed.